Head-to-head · Cost-Efficiency Index
Gala Health vs Direct Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Gala Health
Women who have already committed to a full year and want one all-doses-included rate — plus, unusually, an HRT and menopause line running on the same account as the weight program.
Visit Gala HealthDirect Meds
Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Visit Direct MedsThe verdict
Gala Health and Direct Meds tie on the Cost-Efficiency Index at 71/100, so neither wins outright on the numbers. For most shoppers we'd start with Gala Health (ranked #63, a hair above #64) — Women who have already committed to a full year and want one all-doses-included rate — plus, unusually, an HRT and menopause line running on the same account as the weight program. But Direct Meds is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Gala Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Gala Health | Direct Meds |
|---|---|---|
| Cost-Efficiency Index | 71/100 | 71/100 |
| Semaglutide / mo | No compounded option — brand Ozempic only, $1,299/mo | $249/mo (sublingual, 90-day supply billed monthly) |
| Tirzepatide / mo | $179/mo (yearly subscription; $199/mo on a 3-month plan) | $299/mo (sublingual, 90-day supply billed monthly) |
| Semaglutide / yr (modeled) | — | $2,988 |
| Tirzepatide / yr (modeled) | $2,148 | $3,588 |
| Coverage | 50 states claimed, no list published | Not disclosed |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #63 | #64 |
Gala Health
71/100Where the value is
- $179/mo on a yearly subscription, with every dose included, so the price does not climb as you titrate — dose escalation is where most flat-looking programs quietly get expensive
- The price list is PUBLIC and un-gated: the weight tier, the $149 microdosing tier and the brand tier are all printed before any quiz, intake or email capture
- Both compounded molecules — semaglutide and tirzepatide — prescribable on one account
The tradeoffs
- No month-to-month price exists anywhere on the site. "FROM $179/month" sits directly above "All doses included. Yearly subscription.", and the cheapest alternative the FAQ names is "$199 per month (with a 3-month plan)" — three months is the shortest published commitment there is
- $179/mo is $2,148 committed for the year, and that total is printed nowhere: the site quotes a monthly figure for a purchase it only sells annually, which is the single hardest cost in this ranking to compare against a rate you can cancel next month
Direct Meds
71/100Where the value is
- Sublingual AND injection on BOTH molecules — four GLP-1 SKUs, the widest formulation range of any provider in this ranking
- Every price is published per SKU in a public shop, with no quiz, intake or email capture in front of it
- Each product page prints a per-day equivalent beside the monthly rate ($8.03/day at $249), which is unusually concrete for this category
The tradeoffs
- $249/mo sublingual is well above this ranking's ~$144 median, and the injection route is $297 — the cheapest thing here is dearer than most rows' headline price
- The only purchasable option on every product page is a 90-DAY SUPPLY billed monthly, so three months is the smallest unit sold — there is no month-to-month rate to compare against the rows beside it
Regulatory note: the FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We still list and link to Direct Meds; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.